Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Nickerson, Nicole K ^a   Mohammad, Khalid S ^a,b   Gilmore, Jennifer L ^a   Crismore, Erin ^a   Bruzzaniti, Angela ^a,c   Guise, Theresa A ^a,b   Foley, John ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BETACELLULIN; CD31 ANTIGEN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GELATINASE B; HEPATING BINDING EPIDERMAL GROWTH FACTOR; KI 67 ANTIGEN; NEUTRALIZING ANTIBODY; PARATHYROID HORMONE RELATED PROTEIN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOPROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BODY FAT; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAMMARY FAT PAD; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PARACRINE SIGNALING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; TRABECULAR BONE; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BONE; BONE DEVELOPMENT; BREAST TUMOR; GENETICS; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UDDER;

MUS MUSCULUS;

ANIMALS; BONE AND BONES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAMMARY GLANDS, ANIMAL; MICE; MICE, NUDE; OSTEOGENESIS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; X-RAY MICROTOMOGRAPHY;

EID: 84855992589     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030255     Document Type: Article

References (49)

1. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd, (2009) Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 122: 1-8.
2. Gschwind A, Hart S, Fischer OM, Ullrich A, (2003) TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. Embo J 22: 2411-2421.
3. Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, et al. (2005) Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 280: 8503-8512.
4. Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, et al. (2009) Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10: 1115-1127.
5. Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ 2nd, et al. (2009) Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal 21: 212-219.
6. Willmarth NE, Ethier SP, (2006) Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 281: 37728-37737.
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
8. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
9. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
10. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103: 250-263.
11. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28: 1684-1691.
12. Kenny PA, Bissell MJ, (2007) Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117: 337-345.
13. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, et al. EGFR signaling in breast cancer: Bad to the bone. Semin Cell Dev Biol.
14. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, et al. (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev.
15. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, et al. (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12: 6213s-6216s.
16. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature.
17. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, et al. (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765-770.
18. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
19. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, et al. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458.
20. Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, et al. (2008) Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat 110: 493-505.
21. Qin L, Partridge NC, (2005) Stimulation of amphiregulin expression in osteoblastic cells by parathyroid hormone requires the protein kinase A and cAMP response element-binding protein signaling pathway. J Cell Biochem 96: 632-640.
22. Qin L, Qiu P, Wang L, Li X, Swarthout JT, et al. (2003) Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem 278: 19723-19731.
23. Yang J, Shah R, Robling AG, Templeton E, Yang H, et al. (2008) HMGB1 is a bone-active cytokine. J Cell Physiol 214: 730-739.
24. Berthon P, Goubin G, Dutrillaux B, Degeorges A, Faille A, et al. (1992) Single-steep transformation of human breast epithelial cells by SV40 large T oncogene. Int J Cancer 52: 92-97.
25. Gerstenfeld LC, Alkhiary YM, Krall EA, Nicholls FH, Stapleton SN, et al. (2006) Three-dimensional reconstruction of fracture callus morphogenesis. J Histochem Cytochem 54: 1215-1228.
26. Mohammad KS, Chirgwin JM, Guise TA, (2008) Assessing new bone formation in neonatal calvarial organ cultures. Methods Mol Biol 455: 37-50.
27. Bhagavathula N, Nerusu KC, Fisher GJ, Liu G, Thakur AB, et al. (2005) Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice. Am J Pathol 166: 1009-1016.
28. Allen MR, Ruggiero SL, (2009) Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67: 1373-1377.
29. Bruzzaniti A, Neff L, Sandoval A, Du L, Horne WC, et al. (2009) Dynamin reduces Pyk2 Y402 phosphorylation and SRC binding in osteoclasts. Mol Cell Biol 29: 3644-3656.
30. Davidson NE, Gelmann EP, Lippman ME, Dickson RB, (1987) Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223.
31. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW, (1999) Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism. Cancer Res 59: 5475-5478.
32. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, et al. (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895.
33. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, et al. (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465.
34. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, et al. (2005) Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65: 5278-5283.
35. Roda JM, Sumner LA, Evans R, Phillips GS, Marsh CB, et al. Hypoxia-Inducible Factor-2{alpha} Regulates GM-CSF-Derived Soluble Vascular Endothelial Growth Factor Receptor 1 Production from Macrophages and Inhibits Tumor Growth and Angiogenesis. J Immunol 187: 1970-1976.
36. Voloshin T, Gingis-Velitski S, Bril R, Benayoun L, Munster M, et al. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood.
37. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
38. Hens JR, Wysolmerski JJ, (2005) Key stages of mammary gland development: molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Res 7: 220-224.
39. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, et al. (1999) Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126: 2739-2750.
40. Ciarloni L, Mallepell S, Brisken C, (2007) Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci U S A 104: 5455-5460.
41. Sebastian J, Richards RG, Walker MP, Wiesen JF, Werb Z, et al. (1998) Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ 9: 777-785.
42. Furugaki K, Moriya Y, Iwai T, Yorozu K, Yanagisawa M, et al. (2011) Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis.
43. Gilmore JL, Gonterman RM, Menon K, Lorch G, Riese DJ 2nd, et al. (2009) Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Mol Cancer Res 7: 1714-1728.
44. Lorch G, Gilmore JL, Koltz PF, Gonterman RM, Laughner R, et al. (2007) Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. Br J Cancer 97: 183-193.
45. Lee JE, Chung KW, Han W, Kim SW, Shin HJ, et al. (2004) Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells. Anticancer Res 24: 3961-3964.
46. Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ, (2008) A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer 99: 1056-1063.
47. Balbis A, Posner BI, (2010) Compartmentalization of EGFR in cellular membranes: role of membrane rafts. J Cell Biochem 109: 1103-1108.
48. Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, et al. (2011) Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med 16: 1141-1146.
49. Park SI, Soki FN, McCauley LK, (2011) Roles of Bone Marrow Cells in Skeletal Metastases: No Longer Bystanders. Cancer Microenviron.